IP Library Granted Patent US 10,400,244
Granted Patent B2
US 10,400,244 · App. 15/529,577 · Granted Sep 3, 2019

Oligonucleotide sequence for use in pathway engineering

Inventors: Zdravko Dragovic (Munich, DE); Christoph Reisinger (Munich, DE); Heiko Dietz (Munich, DE)
Assignee: Clariant International Ltd.
C12N15/1137C12N15/113C12Y503/01005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,400,244
App. No.
15/529,577
Granted
Sep 3, 2019
Kind
B2
Abstract

The present invention comprises a novel artificial oligonucleotide sequence which can initiate the transcription of a gene under various conditions at a high level. Further the invention relates to a recombinant DNA fragment comprising the artificial oligonucleotide sequence, an expression plasmid comprising the recombinant DNA fragment and a host cell transformed with the recombinant DNA fragment.

Claims (12)

1. An oligonucleotide comprising a sequence at least 90% identical to SEQ ID NO: 1; wherein said oligonucleotide, when present in yeast cells cultivated in the presence of glucose, mannose, ethanol, glycerol, or xylose, increases growth of the yeast cells.

2. The oligonucleotide of claim 1 , wherein said sequence is at least 95% identical to SEQ ID NO: 1.

3. The oligonucleotide of claim 2 , wherein said sequence is at least 98% identical to SEQ ID NO: 1.

4. The oligonucleotide of claim 3 , wherein said sequence is at least 99% identical to SEQ ID NO: 1.

5. The oligonucleotide of claim 1 , wherein said sequence is selected from the group consisting of SEQ ID NOS: 2-7.

6. The oligonucleotide of claim 1 , wherein the oligonucleotide, when present in yeast cells cultivated in the presence of glucose, mannose, ethanol, glycerol, or xylose, increases expression of XylA mRNA in the cells.

7. The oligonucleotide of claim 6 , wherein the increase in XylA mRNA expression is about 4-fold to about 29-fold.

8. The oligonucleotide of claim 1 , wherein the oligonucleotide, when present in yeast cells cultivated in the presence of glucose, mannose, ethanol, glycerol, or xylose, increases expression of xylose isomerase enzyme activity in the cells.

9. The oligonucleotide of claim 8 , wherein the increase in xylose isomerase enzyme activity expression is about 14-fold to about 25-fold.

10. A recombinant DNA fragment comprising said sequence of claim 1 .

11. A yeast cell expression plasmid comprising at least one recombinant DNA fragment of claim 10 .

12. A yeast cell comprising the plasmid of claim 11 .

Assignments (2)
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE MAY 1, 2018 Recorded Nov 2, 2022
From: CLARIANT INTERNATIONAL LTD
To: CLARIANT PRODUKTE (DEUTSCHLAND) GMBH
Reel/Frame 061875/0121 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2017
From: DRAGOVIC, ZDRAVKO; REISINGER, CHRISTOPH; DIETZ, HEIKO
To: CLARIANT INTERNATIONAL LTD.
Reel/Frame 043041/0230 →
Priority Claims (1)
EP 14195026 · Nov 26, 2014 · regional
Continuity (1)
Related Publication 20170314029A1 · Nov 2, 2017
Cited By (1)
US 12,215,325